

IN THE MATTER OF American Patent in
the names of CENTRE NATIONAL DE LA
RECHERCHE SCIENTIFIQUE, IFREMER
filed under n° 10/030,231

I, Béatrice ORES,
36, rue de Saint-Petersbourg
75008 PARIS (FRANCE)

do solemnly and sincerely declare as follows:


1. that I am a qualified Patent Engineer and am well
acquainted with both the French and English languages,
2. that the attached document is a true and correct
translation of the specification n° 99 08858

filed by CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE, IFREMER, with their application for a Patent in
France on July 8, 1999.

for: "ANTIMICROBIAL PEPTIDES DERIVED FROM MOLLUSKS."

Declared by the said

Béatrice ORES



At Paris on December 22, 2003

ANTIMICROBIAL PEPTIDES DERIVED FROM MOLLUSCS

The invention relates to novel antimicrobial peptides produced by mollusks.

5

Polypeptides possessing antimicrobial properties are produced by a large variety of species (animal or plant species), in which they contribute to nonspecific mechanisms of defense against infections.

10

In the case of bivalve mollusks, to date, in *Mytilus galloprovincialis*, a peptide named MGD-1 has been identified, which is related to insect defensins [HUBERT et al., Eur. J. Biochem., 240, 302-306, (1996)]; peptides of the defensin family have also been demonstrated in *Mytilus edulis*, as have peptides named "mytilins" [CHARLET et al., J. Biol. Chem., 271, 21808-21813, (1996)].

15

20 The inventors have now demonstrated novel antimicrobial peptides produced by *Mytilus galloprovincialis*, which are different from the MGD1 defensins and form the previously known mytilins.

25 A subject of the present invention is antimicrobial peptides, hereinafter named: "myticins", which have the following characteristics:

- their molecular mass is approximately 4.5 kDa;
- 30 - their pI is approximately 8.7;
- they comprise 8 cysteine residues.

According to a preferred embodiment of an antimicrobial peptide in accordance with the invention, it comprises
35 the following sequence (I) (1-letter code):

HX₁HX₂CTSYX₃CX₄KFCGTAX₅CTX₆YX₇CRX₈LHX₉GKX₁₀CX₁₁CX₁₂HCSR (I)

- 2 -

in which: $X_1 = P$ or S , $X_2 = V$ or A , $X_3 = Y$ or W , $X_4 = S$ or G , $X_5 = S$ or G , $X_6 = R$ or H , $X_7 = G$ or L , $X_8 = N$ or V , $X_9 = R$ or P , $X_{10} = L$ or M , $X_{11} = F$ or A , and $X_{12} = L$ or H .

5

Advantageously, a peptide in accordance with the invention comprises one of the following sequences (Ia) or (Ib) (1-letter code):

10 HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR (Ia)
HPHVCTSYIYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR (Ib)

The sequences (Ia) and (Ib) represent the mature forms, isolated from the hemolymph of *Mytilus galloprovincialis*, of 2 myticins named Myticin a and Myticin b, the cDNAs of which have also been cloned by the inventors. By way of illustration of the subject of the present invention, the characteristics of Myticin a and Myticin b are more specifically indicated below.

20

The cDNA sequence and the polypeptide sequence of Myticin a are represented in the attached sequence listing, under the numbers SEQ ID NO: 1 and SEQ ID NO: 2. The cDNA sequence and the polypeptide sequence of Myticin b are represented in the attached sequence listing, under the numbers SEQ ID NO: 3 and SEQ ID NO: 4.

30 The 40 amino acid active peptide, corresponding to the sequence (I), and more particularly to one of the sequences (Ia) and (Ib), is flanked by a 20 amino acid signal sequence and by a 36 amino acid C-terminal peptide. The signal sequence is thought to enable the addressing of the translation product toward the
35 endoplasmic reticulum. The C-terminal peptide would then enable addressing toward the cytoplasmic granules in which the myticins are stored in mature form, and/or protection of the cell against possible cytolytic activity of the mature peptide.

- 3 -

The molecular mass of the mature form of Myticin a is 4438 Da; the molecular mass of the mature form of Myticin b is 4562 Da.

5

Myticins exhibit no significant homology with the known antimicrobial peptides in the prior art, and define a novel group of antimicrobial peptides.

10 Myticins may be obtained by extraction from the mollusks which produce them, by peptide synthesis or, advantageously, by genetic engineering, expressing at least one nucleic acid sequence encoding a myticin, in a suitable host cell.

15

The present invention also encompasses nucleic acids comprising a sequence encoding a myticin, as defined above.

20 Nucleic acids in accordance with the invention may be obtained by screening nucleic acid libraries using oligonucleotides derived from the sequences SEQ ID NO: 1 or SEQ ID NO: 3, or from the sequences complementary thereto. The oligonucleotides which can be used
25 for this purpose are also part of the subject of the present invention; advantageously, these oligonucleotides comprise at least 15 bp, and preferably at least 20 bp, of the coding region of one of the sequences SEQ ID NO: 1 or SEQ ID NO: 3, or of the sequence comple-
30 mentary thereto.

The nucleic acids in accordance with the invention also encompass the expression cassettes comprising at least one nucleic acid sequence encoding a myticin, placed
35 under the transcriptional control of a suitable promoter.

The term "suitable promoter" is intended to mean any promoter which is functional in the host cell intended

- 4 -

to harbor the expression cassette. It may be a constitutive promoter or an inducible promoter; it may also be, when the cassette is intended for the expression of a mytacin in an animal or a plant, a tissue-specific promoter.

An expression cassette in accordance with the invention may also comprise at least one sequence encoding a suitable addressing sequence; said addressing sequence may be chosen from those which are naturally associated with myticins, such as the signal sequences and/or the C-terminal sequences associated with the Mytacin a and Mytacin b isoforms described above; it is also possible to choose one or more heterologous addressing sequences which are functional in a given host cell: they may in particular be sequences which allow the addressing of a mytacin toward a given cellular compartment, or its secretion into the culture medium.

A subject of the invention is also:

- recombinant vectors, characterized in that they comprise at least one nucleic acid sequence in accordance with the invention, encoding a mytacin, and, in particular, vectors comprising an expression cassette as defined above.

- prokaryotic or eukaryotic cells transformed with at least one nucleic acid sequence in accordance with the invention. They may be cells in culture or cells which form part of an animal or plant multicellular organism. The nucleic acid sequence in accordance with the invention present in a transformed cell may be either incorporated into the chromosomal DNA of said cell, or be carried by an extrachromosomal vector.

A subject of the invention is also a method for producing a mytacin, characterized in that it comprises

- 5 -

expressing said myticin in at least one transformed cell in accordance with the invention.

The myticins in accordance with the invention may be
5 expressed in cultures of cells transformed using techniques similar to those used for antimicrobial peptides of the prior art, for example in insect cells, as described by HELLERS et al. [Eur. J. Biochem. 199, pp. 435-439, (1991)] for cecropins, or in yeast, as
10 described by REICHHART et al. [Invertebrate Reproduction and Development, 21, pp. 15-24, (1992)].

They may also be expressed in transgenic animals or plants, in order to increase the resistance thereof to
15 infections, as described, for example, by JAYNES et al. [Plant Science, 89, pp. 43-53 (1993)] in the case of peptides analogous to cecropin B, expressed in transgenic tobacco plants, or by NORELLI et al. [Euphytica, 77, pp. 123-128 (1994)] for transgenic apple tree plants
20 expressing the attacin-E gene.

The myticins can be used in particular for producing anti-infectious, for example antibacterial or fungicidal, products, and in particular medicinal
25 products.

Such products are applied for preventing and treating various microbial diseases, in very varied sectors, in particular in the domains of health and of agriculture,
30 and in that of aquaculture, in order to limit the development of infectious diseases in breeding stocks.

The present invention will be more clearly understood from the further description which follows, which
35 refers to examples of purification and of characterization of the myticins.

- 6 -

**EXAMPLE 1: ISOLATION OF ANTIMICROBIAL PEPTIDES FROM THE
HEMOLYMPH OF MYTILUS GALLOPROVINCIALIS****Preparation of the hemolymph fractions**

5

An immune reaction is induced in adult mussels (*Mytilus galloprovincialis*) according to the following protocol: the liquid is removed from the shell, and 100 µl of a suspension of bacteria (10^9 bacteria/ml) or of fungi (suspension of hyphae at 1 OD at 600 nm), heat-killed
10 beforehand, are injected into the adductor muscle. The hemolymph (approximately 0.5 ml/animal) is removed from the posterior adductor muscle using a syringe, in the presence of one volume of MAS (Modified Alsevier
15 Solution) anti-aggregating buffer, and immediately centrifuged at 800g for 15 min at 4°C. Aprotinin (5 µg/ml) is added to the supernatant, corresponding to the plasmatic fraction, which is frozen (-80°C) until
20 use, and the cell pellet is dried and stored at -80°C until use.

Purification of myticins

Plasmatic fraction: The plasma is diluted (1:1 v/v) in
25 water sterilized by ultrafiltration (MilliQ), to which 0.1% of trifluoroacetic acid has been added. The pH is brought to 3.9 by adding 1 M HCl, with stirring, in an iced water bath for 30 min. After centrifugation (10 000 g, 20 min, 4°C), the supernatant is harvested
30 and kept at 4°C until use.

Hemocytes: After thawing, the hemocyte pellet is resuspended in 5 volumes of 50 mM Tris buffer, pH 8.7, containing 50 mM NaCl, and homogenized. After centri-
35 fugation (10 000 g, 20 min, 4°C), the pellet containing the cellular organelles is taken up in 3 volumes of 2 M acetic acid and treated by sonication (3 × 30 s) in an iced water bath. After removal of the debris by

- 7 -

centrifugation (10 000 g, 20 min, 4°C), the acid extract is stored at 4°C until use.

HPLC purification

5

The plasmatic fraction or the acid extracts of hemocytes are loaded onto SEP-PAK C18 VAC columns (WATERS ASSOCIATES) pre-equilibrated with acidified (0.05% trifluoroacetic acid) water. After washing with
10 the acidified water, 2 successive elutions are carried out with solutions of acetonitrile at 10% and 40% in acidified (0.05% trifluoroacetic acid) water. The fractions obtained are lyophilized and reconstituted with ultrafiltered water, before being subjected to
15 reverse-phase HPLC chromatography.

All the HPLC purification steps were carried out on a BECKMAN GOLD HPLC system equipped with a BECKMAN 168 detector. The elution is monitored by measuring UV
20 absorption at 225 nm.

Step 1: The fractions eluted on SEP-PAK at 40% of acetonitrile are loaded onto a SEPHASIL C18 reverse-phase HPLC column (250 mm × 4.1 mm) (PHARMACIA). Elution
25 is carried out with a linear gradient of 5 to 50% of acetonitrile in the acidified water, for 90 min at a flow rate of 0.9 ml/min. The fractions corresponding to the absorbence peaks are collected in polypropylene tubes (MICROSORB, 75 × 12 mm, NUNC IMMUNOTUBES), dried
30 under vacuum and reconstituted with ultrafiltered water, prior to testing their antimicrobial activity.

Step 2: The active fractions recovered at the end of step 1 are loaded onto a SEPHASIL C8 reverse-phase HPLC
35 column (250 mm × 4.1 mm) (PHARMACIA). The elution is carried out, at a flow rate of 0.9 ml/min, with a linear gradient of 20 to 30% of acetonitrile in the acidified water for 40 min.

- 8 -

Step 3: The active fractions recovered at the end of step 2 are loaded onto a SEPHASIL C18 column (250 mm × 4.1 mm) (PHARMACIA), using the biphasic gradient described in step 2, at a flow rate of 0.9 ml/min.

5

Step 4: The final purification step is carried out on a DELTA PAK HPI C18 reverse-phase column (2 × 150 mm) (WATERS ASSOCIATES), using the biphasic gradient described in step 2, at a flow rate of 0.3 ml/min.

10

EXAMPLE 2: ANTIMICROBIAL ACTIVITY OF THE PEPTIDES OBTAINED

Microorganisms used:

15

The list of the microorganisms used to determine the antimicrobial activities of Myticin a and of Myticin b is indicated below, in table 1.

Antibacterial assays and determination of the MBC:

20

The minimum bactericidal concentration (MBC) of the peptides was determined according to the protocol described by HANCOCK et al. [<http://www.interchg.ubc.ca/bobh/methods.htm>].

25

A series of successive doubling dilutions of the peptides, in an aqueous solution containing 0.01% of acetic acid and 0.2% of bovine serum albumin (BSA), is prepared.

30

10 µl aliquots of each dilution are incubated in sterile 96-well polypropylene microtitration plates, in the presence of 100 µl of bacterial suspension at a starting optical density of $A_{600} = 0.001$, in MUELLER HINTON BROTH liquid medium. The incubation is carried out for 18 h at 37°C with stirring, except in the case of the marine bacteria, for which the incubation is carried out 25°C. The MBC is determined by plating out,

35

- 9 -

onto solid MUELLER HINTON AGAR medium, the content of the wells corresponding to the first 3 dilutions for which no bacterial growth is observed, and incubating at 37°C for 18 hours. The lowest concentration of peptide which prevents any residual formation of colonies corresponds to the MBC.

Antifungal activity:

10 The antifungal activity was determined by calculating the MIC (minimum inhibitory concentration) in a test of inhibition of *Fusarium oxysporum* growth in liquid phase, according to the protocol described by FELHBAUM et al. [J. Biol. Chem., 269: 33159-63, (1994)].

15

A series of successive doubling dilutions of the peptides is prepared as indicated above for determining the antibacterial activity.

20 80 µl of spores suspended (final concentration 10^4 spores/ml) in Potato Dextrose Broth medium (DIFCO) are added to 10 µl of peptide solution in sterile 96-well polypropylene microtitration plates. The final volume is adjusted to 100 µl by adding water. The growth inhibition is determined after incubation for 24 hours at 25°C in the dark, by observation under a microscope and measurement of the increase in the OD₆₀₀. The value of the MIC corresponds to a range (a-b) of peptide concentrations, in which (a) represents the highest concentration at which growth is observed, and (b) represents the lowest concentration which induces 100% growth inhibition.

Antiprotozoan activity:

35

The oyster-parasite protozoan *Perkinsus marinus* is cultured in DMEM medium (GIBCO), according to the protocol described by GAUTHIER and VASTA [J. Invertebr. Pathol., 66, 156-168, (1995)].

- 10 -

10 μ M of purified peptide are added to 4×10^4 *P. marinus*, in seawater (final volume 20 μ l). The mixture is incubated for 1 hour at room temperature. The viability of the parasites is estimated by staining with acridine orange and with ethidium bromide, as described by MORVAN et al. [J. Invertebr. Pathol., 69, 177-82 (1997)]. The maximum viability is evaluated, as a positive control, in samples to which the peptide has not been added.

The results of the various experiments carried out, for the Mytacin a and Mytacin b peptides, are illustrated by table 1 below; the biological activities are expressed in μ M.

TABLE 1

	Mytacin a	Mytacin b
BACTERIA		
Gram-positive		
<i>Micrococcus luteus</i>	2.25-4.5	1-2
<i>Bacillus megaterium</i>	2.25-4.5	1-2
<i>Staphylococcus aureus</i>	>20	>20
<i>Listeria monocytogenes</i>	>20	>20
<i>Aerococcus viridans</i>	4.5-9	2-4
<i>Enterococcus faecalis</i>	>20	N.D.
Gram-negative		
<i>Escherichia coli</i> D31	>20	10-20
<i>Salmonella newport</i>	>20	>20
<i>S. typhimurium</i>	>20	>20
<i>Brucella suis</i>	>20	>20
<i>Pseudomonas aeruginosa</i>	>20	N.D.
<i>Enteromonas aerogenes</i>	>20	N.D.
<i>Vibrio alginolyticus</i>	>20	>20
<i>V. vulnificus</i>	>20	>20
<i>V. splendidus</i>	>20	>20

- 11 -

	Myticin a	Myticin b
FUNGI		
<i>Fusarium oxysporum</i>	>20	5-10
OYSTER-PARASITE PROTOZOAN		
<i>Perkinsus marinus</i>	>20	>20

N.D.: not determined

These results show that the 2 peptides are active, in particular on *Micrococcus luteus*; the Myticin b peptide also appears to be more active than the Myticin a peptide on *Micrococcus luteus*, *Escherichia coli* and *Fusarium oxysporum*.

EXAMPLE 3: MYTICIN PEPTIDE cDNA CLONING

10

A cDNA library was constructed in the ZAP EXPRESS vector (STRATAGENE) using total poly(A)⁺ RNAs from adult mussel hemocytes. A DNA probe representing 83 bp of the Myticin a cDNA was constructed using the PCR
 15 SCRIPT Amp (SK+) cloning kit (STRATAGENE), and labeled by random priming using the READY-TO-GO DNA labeling kit (PHARMACIA), and used to screen the DNA library transferred onto HYBOND-N membranes (AMERSHAM). Hybridizations at high stringency were carried out
 20 overnight at 65°C in 5X Denhardt's solution, 5X SSPE, 0.1% SDS, 100 µg/ml of salmon sperm DNA. The filters, rinsed beforehand at 65°C in 0.5 X SSC solution containing 0.1% SDS, were autoradiographed. A secondary screening was carried out in order to purify the
 25 positive clones. The phagemids were obtained by *in vivo* excision and both of their strands were sequenced.

110 positive clones were obtained. Among these clones, 4 were sequenced, and correspond to the Myticin a and
 30 Myticin b peptides.

In both cases, the amino acid sequence deduced from the open reading frame begins with a 20 amino acid signal

- 12 -

peptide; this signal peptide is directly followed, at its C-terminal end, by a 40 amino acid peptide beginning with a histidine residue, which corresponds to the active form of the peptide; this active peptide
5 is followed by a 36 amino acid C-terminal extension.